GERON CORP Increase (Decrease) in Operating Liabilities
GERON CORP (GERN) reported Increase (Decrease) in Operating Liabilities of -$114.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLiabilities · last filed 2025-11-07
- GERON CORP increase (decrease) in operating liabilities for the quarter ending 2025-09-30 was $21.37M, a 123.54% increase year-over-year.
- GERON CORP increase (decrease) in operating liabilities for the quarter ending 2025-06-30 was -$863.00K, a 117.94% decline year-over-year.
- GERON CORP increase (decrease) in operating liabilities for the quarter ending 2025-03-31 was -$20.62M.
- GERON CORP increase (decrease) in operating liabilities for the quarter ending 2024-09-30 was $9.56M, a 81.09% increase year-over-year.
| Period end | Increase (Decrease) in Operating Liabilities 3 month | Increase (Decrease) in Operating Liabilities 6 month | Increase (Decrease) in Operating Liabilities 9 month |
|---|---|---|---|
| 2025-09-30 | $21.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $20.51M derived: sum of 2 quarters · filed 2025-11-07 | -$114.00K 10-Q · filed 2025-11-07 |
| 2025-06-30 | -$863.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$21.48M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | -$20.62M 10-Q · filed 2025-05-07 | ||
| 2024-09-30 | $9.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $14.37M derived: sum of 2 quarters · filed 2025-11-07 | $4.65M 10-Q · filed 2025-11-07 |
| 2024-06-30 | $4.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$4.91M 10-Q · filed 2025-08-06 | |
| 2024-03-31 | -$9.72M 10-Q · filed 2025-05-07 | ||
| 2023-09-30 | $5.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $23.08M derived: sum of 2 quarters · filed 2024-11-07 | $11.08M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $17.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $5.80M 10-Q · filed 2024-08-08 | |
| 2023-03-31 | -$12.00M 10-Q · filed 2024-05-02 | ||
| 2022-09-30 | $27.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $22.92M derived: sum of 2 quarters · filed 2023-11-02 | $23.89M 10-Q · filed 2023-11-02 |
| 2022-06-30 | -$5.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$4.09M 10-Q · filed 2023-08-03 | |
| 2022-03-31 | $967.00K 10-Q · filed 2023-05-11 | ||
| 2021-09-30 | $1.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $9.65M derived: sum of 2 quarters · filed 2022-11-07 | $7.14M 10-Q · filed 2022-11-07 |
| 2021-06-30 | $8.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $5.79M 10-Q · filed 2022-08-11 | |
| 2021-03-31 | -$2.52M 10-Q · filed 2022-05-09 | ||
| 2020-09-30 | $4.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $20.78M derived: sum of 2 quarters · filed 2021-11-09 | $8.74M 10-Q · filed 2021-11-09 |
| 2020-06-30 | $15.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $3.85M 10-Q · filed 2021-08-16 | |
| 2020-03-31 | -$12.04M 10-Q · filed 2021-05-10 | ||
| 2019-09-30 | $2.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $5.49M derived: sum of 2 quarters · filed 2019-11-06 | $3.46M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $2.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $894.00K 10-Q · filed 2019-08-01 | |
| 2019-03-31 | -$2.03M 10-Q · filed 2020-05-28 | ||
| 2018-09-30 | -$438.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $82.00K derived: sum of 2 quarters · filed 2019-11-06 | -$2.05M 10-Q · filed 2019-11-06 |
| 2018-06-30 | $520.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | -$1.61M 10-Q · filed 2019-08-01 | |
| 2018-03-31 | -$2.13M 10-Q · filed 2019-05-02 | ||
| 2017-09-30 | -$5.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | -$1.90M 10-Q · filed 2018-11-01 | |
| 2017-06-30 | $3.40M 10-Q · filed 2018-07-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |